BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tan AH, Lim S, Mahadeva S, Loke MF, Tan JY, Ang BH, Chin KP, Mohammad Adnan AF, Ong SMC, Ibrahim AI, Zulkifli N, Lee JK, Lim WT, Teo YT, Kok YL, Ng TY, Tan AGS, Zulkifle IM, Ng CK, Ee SS, Arafin S, Mohamad Shukori K, Vadivelu JS, Marras C, Fox SH, Lang AE. Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial. Mov Disord 2020;35:2250-60. [DOI: 10.1002/mds.28248] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Linard M, Ravier A, Mougué L, Grgurina I, Boutillier AL, Foubert-Samier A, Blanc F, Helmer C. Infectious Agents as Potential Drivers of α-Synucleinopathies. Mov Disord 2022. [PMID: 35040520 DOI: 10.1002/mds.28925] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Tan AH, Hor JW, Chong CW, Lim SY. Probiotics for Parkinson's disease: Current evidence and future directions. JGH Open 2021;5:414-9. [PMID: 33860090 DOI: 10.1002/jgh3.12450] [Reference Citation Analysis]
3 Bindas AJ, Kulkarni S, Koppes RA, Koppes AN. Parkinson's disease and the gut: Models of an emerging relationship. Acta Biomater 2021;132:325-44. [PMID: 33857691 DOI: 10.1016/j.actbio.2021.03.071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Brown EG, Goldman SM. Modulation of the Microbiome in Parkinson's Disease: Diet, Drug, Stool Transplant, and Beyond. Neurotherapeutics 2020;17:1406-17. [PMID: 33034846 DOI: 10.1007/s13311-020-00942-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Safarpour D, Sharzehi K, Pfeiffer RF. Gastrointestinal Dysfunction in Parkinson’s Disease. Drugs. [DOI: 10.1007/s40265-021-01664-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Luo S, Goetz CG, Choi D, Aggarwal S, Mestre TA, Stebbins GT. Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine. Mov Disord 2022. [PMID: 35716143 DOI: 10.1002/mds.29129] [Reference Citation Analysis]
7 Kramer P. Mitochondria-Microbiota Interaction in Neurodegeneration. Front Aging Neurosci 2021;13:776936. [PMID: 35002678 DOI: 10.3389/fnagi.2021.776936] [Reference Citation Analysis]
8 Tan AH, Chong CW, Lim SY, Yap IKS, Teh CSJ, Loke MF, Song SL, Tan JY, Ang BH, Tan YQ, Kho MT, Bowman J, Mahadeva S, Yong HS, Lang AE. Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-Omics. Ann Neurol 2021;89:546-59. [PMID: 33274480 DOI: 10.1002/ana.25982] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
9 Pavan S, Prabhu AN, Prasad Gorthi S, Das B, Mutreja A, Shetty V, Ramamurthy T, Ballal M. Exploring the multifactorial aspects of Gut Microbiome in Parkinson's Disease. Folia Microbiol (Praha) 2022. [PMID: 35583791 DOI: 10.1007/s12223-022-00977-2] [Reference Citation Analysis]
10 Fan HX, Sheng S, Zhang F. New hope for Parkinson's disease treatment: Targeting gut microbiota. CNS Neurosci Ther 2022. [PMID: 35822696 DOI: 10.1111/cns.13916] [Reference Citation Analysis]
11 Bai F, Li X. Association of Helicobacter pylori treatment with Parkinsonism and related disorders: A systematic review and meta-analysis. Life Sci 2021;281:119767. [PMID: 34216625 DOI: 10.1016/j.lfs.2021.119767] [Reference Citation Analysis]
12 Zheng SY, Li HX, Xu RC, Miao WT, Dai MY, Ding ST, Liu HD. Potential roles of gut microbiota and microbial metabolites in Parkinson's disease. Ageing Res Rev 2021;69:101347. [PMID: 33905953 DOI: 10.1016/j.arr.2021.101347] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
13 Sun X, Xue L, Wang Z, Xie A. Update to the Treatment of Parkinson's Disease Based on the Gut-Brain Axis Mechanism. Front Neurosci 2022;16:878239. [PMID: 35873830 DOI: 10.3389/fnins.2022.878239] [Reference Citation Analysis]
14 Huang Y, Liao J, Liu X, Zhong Y, Cai X, Long L. Review: The Role of Intestinal Dysbiosis in Parkinson's Disease. Front Cell Infect Microbiol 2021;11:615075. [PMID: 33968794 DOI: 10.3389/fcimb.2021.615075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Skjærbæk C, Knudsen K, Horsager J, Borghammer P. Gastrointestinal Dysfunction in Parkinson's Disease. J Clin Med 2021;10:493. [PMID: 33572547 DOI: 10.3390/jcm10030493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
16 Lolekha P, Sriphanom T, Vilaichone RK. Helicobacter pylori eradication improves motor fluctuations in advanced Parkinson's disease patients: A prospective cohort study (HP-PD trial). PLoS One 2021;16:e0251042. [PMID: 33945559 DOI: 10.1371/journal.pone.0251042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral levodopa resistance in Parkinson's disease. NPJ Parkinsons Dis 2022;8:56. [PMID: 35546556 DOI: 10.1038/s41531-022-00321-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Di Luca DG, Reyes NGD, Fox SH. Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease. Drugs 2022. [PMID: 35841520 DOI: 10.1007/s40265-022-01747-7] [Reference Citation Analysis]
19 Safikhani Mahmoodzadeh A, Moazamian E, Shamsedin SA, Kaydani GA. Prevalence of Virulence Genes and Antigen Pattern in Helicobacter pylori-Infected Patients and The Level of Some Inflammatory Cytokines Compared with Non-infected Individuals. Jundishapur J Microbiol 2022;15. [DOI: 10.5812/jjm-121144] [Reference Citation Analysis]
20 Berlamont H, Bruggeman A, Bauwens E, Vandendriessche C, Clarebout E, Xie J, De Bruyckere S, Van Imschoot G, Van Wonterghem E, Ducatelle R, Santens P, Smet A, Haesebrouck F, Vandenbroucke RE. Gastric Helicobacter suis Infection Partially Protects against Neurotoxicity in A 6-OHDA Parkinson's Disease Mouse Model. Int J Mol Sci 2021;22:11328. [PMID: 34768765 DOI: 10.3390/ijms222111328] [Reference Citation Analysis]
21 Menozzi E, Macnaughtan J, Schapira AHV. The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance. Ann Med 2021;53:611-25. [PMID: 33860738 DOI: 10.1080/07853890.2021.1890330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. Nat Rev Neurol 2022. [PMID: 35750883 DOI: 10.1038/s41582-022-00681-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]